CARGO Therapeutics Inc. C... (CRGX)
4.18
-0.02 (-0.48%)
At close: Mar 25, 2025, 3:59 PM
4.16
-0.46%
Pre-market: Mar 26, 2025, 07:21 AM EDT
-0.48% (1D)
| Bid | 4.1 |
| Market Cap | 192.5M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -171.53M |
| EPS (ttm) | -3.72 |
| PE Ratio (ttm) | -1.12 |
| Forward PE | -3.4 |
| Analyst | Hold |
| Ask | 4.22 |
| Volume | 404,598 |
| Avg. Volume (20D) | 1,110,577 |
| Open | 4.18 |
| Previous Close | 4.20 |
| Day's Range | 4.12 - 4.23 |
| 52-Week Range | 3.00 - 26.61 |
| Beta | 1.64 |
About CRGX
CARGO Therapeutics, Inc., a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies. It also develops CRG-023, a tri-specific CAR T product candidate that targets tumor cell...
Industry Biotechnology
Sector Healthcare
IPO Date Nov 13, 2023
Employees 167
Stock Exchange NASDAQ
Ticker Symbol CRGX
Website https://cargo-tx.com
Analyst Forecast
According to 7 analyst ratings, the average rating for CRGX stock is "Hold." The 12-month stock price forecast is $4, which is a decrease of -4.31% from the latest price.
Stock Forecasts1 week ago
+9.21%
CARGO Therapeutics shares are trading higher after...
Unlock content with
Pro Subscription
1 month ago
-74.3%
Cargo Therapeutics shares are trading lower after five firms downgraded the stock and Jefferies cut its price target from $32 to $3.
